首页> 外文会议>Vaccine technology VI >A CLICK CHEMISTRY STRATEGY TO SPECIFICALLY MONITOR AND IMPROVE PURIFICATION OF INFLUENZA VIRUS-LIKE PARTICLES
【24h】

A CLICK CHEMISTRY STRATEGY TO SPECIFICALLY MONITOR AND IMPROVE PURIFICATION OF INFLUENZA VIRUS-LIKE PARTICLES

机译:专门用于监测和改善流感病毒样颗粒的纯化化学策略

获取原文
获取原文并翻译 | 示例

摘要

Virus-like particles (VLPs) constitute a promising platform in vaccine development and targeted drug-delivery. However, most applications use simple, non-enveloped VLPs that present less technical challenges, not only to produce and purify, but also in terms of characterization, compared to enveloped VLPs. Recent advances in upstream processing, new product quality requirements and other regulatory issues, as well as the search for more cost-effective processes, led to the need to develop more efficient downstream processes for biopharmaceuticals. In that sense, new monitoring and product characterization methods, which can be applied at all stages of downstream processing, are needed. Here is reported a valuable platform for the downstream processing and monitoring of the in vivo production of site-specifically functionalized enveloped Influenza VLPs. This strategy involves a two-step procedure that consists of residue-specific replacement of methionine by an analog (azidohomolanine) that enabled for post-expression functionalization with a fluorophore. Importantly, this platform does not impact VLP production or purification processes, and allows functionalization without deleterious effect on hemagglutinin biological function. As a proof of concept a complete downstream processing was performed, including clarification, capture and polishing steps. A flow cytometry analysis (FACS) step was added to achieve a refined discrimination and separation between VLPs and baculovirus - the major impurity of the process. This was further confirmed using atomic force microscopy (AFM). This tool allowed to accurately monitor our product, achieve higher product recovery yields and higher impurity removal levels. The versatile system presented here is broadly applicable to the production of functionalized enveloped VLPs, for vaccine design, targeted drug delivery and molecular imaging.
机译:病毒样颗粒(VLP)构成了疫苗开发和靶向药物输送的有前途的平台。但是,与封装的VLP相比,大多数应用程序都使用简单的,无外壳的VLP,这些VLP不仅在生产和纯化方面,而且在表征方面都面临较少的技术挑战。上游加工,新产品质量要求和其他法规问题的最新进展,以及对更具成本效益的工艺的追求,导致需要为生物制药开发更高效的下游工艺。从这个意义上讲,需要新的监测和产品表征方法,这些方法可以应用于下游加工的所有阶段。此处报道了一个有价值的平台,用于下游处理和监测位点特异性功能化包膜流感VLP的体内生产。该策略涉及两步程序,该程序包括通过类似物(叠氮高鸟嘌呤)对甲硫氨酸进行残基特异性取代,该类似物可通过荧光团实现表达后功能化。重要的是,该平台不会影响VLP的生产或纯化过程,并且允许其功能化而不会对血凝素的生物学功能产生有害影响。作为概念验证,执行了完整的下游处理,包括澄清,捕获和抛光步骤。添加了流式细胞仪分析(FACS)步骤,以实现VLP与杆状病毒(该过程的主要杂质)之间的精确区分和分离。使用原子力显微镜(AFM)进一步证实了这一点。该工具可以精确监控我们的产品,实现更高的产品回收率和更高的杂质去除水平。此处介绍的通用系统广泛适用于功能化包膜VLP的生产,用于疫苗设计,靶向药物递送和分子成像。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号